FDA Regulatory Event

The U.S. Food and Drug Administration (FDA) Orange Book approved ANDA 214289 for mycophenolate sodium delayed-release tablets 180mg and 360mg, submitted by TWi Pharmaceuticals, on November 3, 2021, and listed both strengths for discontinuation on March 2026. This product was marketed by Upsher-Smith Laboratories as mycophenolate delayed-release tablets, with an NDC record indicating a marketing stop date of September 30, 2026. Discontinuation listing does not imply approval withdrawal or safety concerns but signals the end of commercial supply for the labeled product.

Drug and Clinical Context

The reference brand is Myfortic from Novartis (NVS), and the generic name is mycophenolate sodium, with mycophenolic acid as the active moiety. This drug is an antimetabolite immunosuppressant that reversibly inhibits inosine monophosphate dehydrogenase (IMPDH), blocking guanosine nucleotide synthesis in lymphocytes. It is used for the prevention of organ rejection in adult renal transplant patients and pediatric patients aged 5 years and older at least 6 months post-transplant. It is an FDA-approved, marketed product, not in the development stage. Myfortic received FDA approval on February 27, 2004, and ANDA review focuses on bioequivalence and quality assessment compared to the reference drug, rather than an advisory committee vote.

Competitive Landscape and Patient Impact

Direct competitors include FDA-approved Myfortic generics from Apotex, Accord Healthcare, Concord Biotech, Biocon Pharma, and Aurobindo Pharma. In clinical practice, Roche (ROG.SW)'s CellCept and generic mycophenolate mofetil, and Astellas Pharma (4503.T)'s Prograf and generic tacrolimus, form the core competitive and combination axis of standard maintenance immunosuppressive therapy. Therefore, the discontinuation of ANDA 214289 does not eliminate treatment options, but it may necessitate supplier transitions and price renegotiations in specific distribution agreements, formularies, and wholesale channels.

Market and Corporate Strategy

The global organ transplant immunosuppressant market is projected to grow from USD 6.03 billion in 2026 to USD 7.51 billion in 2031; however, the mature generic segment is characterized by multiple suppliers and strong price competition. Upsher-Smith Laboratories is a privately held U.S. pharmaceutical company and a subsidiary of Bora Pharmaceuticals (6479.TW). This discontinuation is more of an adjustment of the economics of a low-margin generic portfolio than a focus on growth-stage clinical assets. With competing generics remaining on the market, the overall supply impact on the industry is limited, with a more direct effect being reduced sales for Upsher-Smith and increased prescription volume for competitors.